Eli Lilly, pulverized. Here’s a company that pre-announced $58 to $61 billion in revenue next year, substantially better than expected on the back of those GLP-1 drugs, approved for diabetes ...

After years of preparation, Eli Lilly is on the brink of launching ... head of connected care for Lilly Diabetes. "Using the learnings from early adopters of Tempo, we look forward to continually ...

leader of Eli Lilly and Company's diabetes business unit in Northern Europe, tells pharmaphorum how the company is working to support diabetes care in the UK amid the pandemic. As COVID-19 turned ...

Sales of the company's diabetes and weight loss treatments are soaring but not quite as fast as the company anticipated in the first half of last year. Sales of Eli Lilly's lead drug, tirzepatide ...

2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE: LLY). At one point, share prices had gained as much as 65% on the year. However, after a less-than-spectacular earnings ...

Eli Lilly and Company (NYSE:LLY) will increase its dividend from last year's comparable payment on the 10th of March to $1.50. This takes the annual payment to 0.8% of the current stock price ...

Eli Lilly recently updated Q4 revenue guidance, and sales are expected to come in lower than previously anticipated. While this could suggest the company is experiencing sluggish or plateauing ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels.

Eli Lilly (NYSE ... a sell-off earlier this week after Lilly cut its 2024 revenue guidance due to lower-than-expected demand for its obesity and diabetes drugs. One of Trump's primary pledges ...

(see more details here). Eli Lilly and Company (NYSE:LLY) is a global leader in pharmaceuticals, offering treatments for diabetes, oncology, rheumatoid arthritis, psoriasis, migraines, and more.